SCHEMBL3107192

SCHEMBL3107192

O=C(CCl)c1ccc(-c2ccccc2F)cc1-c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 1/20 0.50
PTPRC P08575 1/20 0.47
PTPN1 P18031 1/20 0.47
ALDH1A1 P00352 3/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPSR1 Q6W5P4 1/20 0.41
PDK2 Q15119 1/20 0.41
HIF1A Q16665 3/20 0.40
MAPK1 P28482 2/20 0.39
DHODH Q02127 2/20 0.38
SLC6A9 P48067 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
TRPA1 O75762 2/20 0.37
GSK3B P49841 1/20 0.37
TNKS O95271 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
GPR35 Q9HC97 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074665 0.80 ACMSD (0.54) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL1427156 0.73 ALDH1A1 (0.59) PTPN1ALDH1A1MAPTHIF1AMAPK1
SCHEMBL29779889 0.73 ALDH1A1 (0.59) PTPN1ALDH1A1MAPTHIF1AMAPK1
SCHEMBL505872 0.72 ACMSD (0.71) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL14252244 0.72 ACMSD (0.76) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL9723098 0.71 NPSR1 (0.47) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL5992835 0.71 ACMSD (0.55) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL3097068 0.71 ACMSD (0.51) ACMSDPTPRCPTPN1ALDH1A1MAPT
SCHEMBL28173338 0.70 ACMSD (0.77) ACMSDPTPRCPTPN1ALDH1A1HIF1A
SCHEMBL28721159 0.70 BCAT2 (0.57) ALDH1A1NPSR1HIF1AMAPK1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR ACMSD 2940/4885PTPRC 2772/4885PTPN1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.